Cardiopulmonary Bypass clinical trials at UCSF

1 in progress, 0 open to eligible people

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Sorry, not currently recruiting here
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who undergo non-emergent cardiac surgery with CPB.
San Francisco, California and other locations

Last updated: February 7, 2024